J&J/Legend’s Carvykti Data Show Earlier-Line Efficacy As Commercial Headwinds Remain
Executive Summary
The companies unblinded data from CARTITUDE-4, which met its primary endpoint, but analysts citing KOLs said they continue to face issues with limited manufacturing slots and out-of-spec product.
You may also be interested in...
US FDA Delay For Abecma In Early MM Gives Carvykti Time To Catch Up
Bristol Myers and 2seventy bio are hoping Abecma will be the first CAR-T therapy for earlier lines of multiple myeloma, but an advisory committee meeting will hold up the sBLA.
2Seventy Cuts Jobs As It Streamlines Pipeline, Focuses On Abecma
Nearly two years after its spin-out from bluebird, 2Seventy is slowing in-house R&D and leaning on partners to conserve cash while BMS-partnered Abecma regains its competitive footing.
BMS To Take Over Novartis Plant In Effort To Boost Viral Vector Production For CAR-Ts
BMS’s myeloma CAR-T, Abecma, has faced manufacturing backlogs, like its rival, J&J and Legend Biotech’s Carvykti, with viral vector shortages playing a significant role.